AR014973A1 - Forma vi de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-bencimidazol, uso del mismo en la preparacion de medicamentos, formulaciones que lacontienen y procesos para su sintesis - Google Patents
Forma vi de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-bencimidazol, uso del mismo en la preparacion de medicamentos, formulaciones que lacontienen y procesos para su sintesisInfo
- Publication number
- AR014973A1 AR014973A1 ARP990101493A ARP990101493A AR014973A1 AR 014973 A1 AR014973 A1 AR 014973A1 AR P990101493 A ARP990101493 A AR P990101493A AR P990101493 A ARP990101493 A AR P990101493A AR 014973 A1 AR014973 A1 AR 014973A1
- Authority
- AR
- Argentina
- Prior art keywords
- beta
- synthesis
- processes
- lacontien
- isopropilamine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describe la forma VI del compuesto antiviral 5-6-dicloro-2-(isopropilamino)-1-beta-L-ribofuranosil-1H-bencimidazol, composiciones farmacéuticas que lacontienen, procesos para su síntesis y su uso en terapia médica. La forma VI de 5,6-dicloro-2-(isopropilamino)-1-beta-L-ribofuranosil-1H-bencimidazol secaracteriza por un patron de difraccion de polvo en rayos X expresado en términos de ángulo 2 theta y obtenido con un difractometro equipado con unmonocromador de grafito de haz difractado usandoradiacion X de cobre K alfa, dicho patron de difraccion en polvo de rayos X comprende un ángulo e theta a 8.53más o menos 0.05 grados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9807355.4A GB9807355D0 (en) | 1998-04-07 | 1998-04-07 | Antiviral compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR014973A1 true AR014973A1 (es) | 2001-04-11 |
Family
ID=10829933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101493A AR014973A1 (es) | 1998-04-07 | 1999-03-31 | Forma vi de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-bencimidazol, uso del mismo en la preparacion de medicamentos, formulaciones que lacontienen y procesos para su sintesis |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US6482939B1 (es) |
| EP (1) | EP1070078B1 (es) |
| JP (1) | JP2002510702A (es) |
| KR (1) | KR100573635B1 (es) |
| CN (1) | CN1222534C (es) |
| AP (1) | AP2000001946A0 (es) |
| AR (1) | AR014973A1 (es) |
| AT (1) | ATE231517T1 (es) |
| AU (1) | AU753527B2 (es) |
| BG (1) | BG104909A (es) |
| BR (2) | BR9909471A (es) |
| CA (1) | CA2327495C (es) |
| CO (1) | CO5011057A1 (es) |
| DE (1) | DE69905025T2 (es) |
| DK (1) | DK1070078T3 (es) |
| EA (1) | EA002953B1 (es) |
| EE (1) | EE04121B1 (es) |
| EG (1) | EG24597A (es) |
| ES (1) | ES2191429T3 (es) |
| GB (1) | GB9807355D0 (es) |
| GE (1) | GEP20022840B (es) |
| HK (1) | HK1032060A1 (es) |
| HR (1) | HRP20000670B1 (es) |
| HU (1) | HUP0101549A3 (es) |
| ID (1) | ID26573A (es) |
| IL (2) | IL138559A0 (es) |
| IS (1) | IS5634A (es) |
| MA (1) | MA26617A1 (es) |
| NO (1) | NO316896B1 (es) |
| NZ (1) | NZ507012A (es) |
| OA (1) | OA11534A (es) |
| PE (1) | PE20000356A1 (es) |
| PL (1) | PL194752B1 (es) |
| PT (1) | PT1070078E (es) |
| SI (1) | SI1070078T1 (es) |
| SK (1) | SK283735B6 (es) |
| TR (1) | TR200002847T2 (es) |
| WO (1) | WO1999051617A2 (es) |
| YU (1) | YU58600A (es) |
| ZA (1) | ZA200005197B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807354D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
| GB0008939D0 (en) | 2000-04-11 | 2000-05-31 | Glaxo Group Ltd | Process for preparing substituted benzimidazole compounds |
| US20110008463A1 (en) * | 2008-03-12 | 2011-01-13 | Jan Pieter Hendrik Bosselaers | Combinations of hydroxypyrion compounds and silver compounds |
| US8940707B2 (en) | 2010-10-28 | 2015-01-27 | Viropharma Incorporated | Maribavir isomers, compositions, methods of making and methods of using |
| US8541391B2 (en) * | 2010-10-28 | 2013-09-24 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole |
| US8546344B2 (en) | 2010-10-28 | 2013-10-01 | Viropharma Incorporated | Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl)-1H-benzimidazole |
| WO2023105483A1 (en) * | 2021-12-10 | 2023-06-15 | Assembly Biosciences, Inc. | Crystalline forms of a 5-aminopyrazole compound useful for treating hbv |
| WO2024081308A1 (en) | 2022-10-12 | 2024-04-18 | Takeda Pharmaceutical Company Limited | Method of preparing maribavir |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3399987A (en) | 1965-08-02 | 1968-09-03 | United States Borax Chem | 2-alkylaminobenzimidazoles as herbicides |
| CH443777A (de) | 1965-08-06 | 1968-02-15 | Agripat Sa | Verfahren zum Schützen textiler Keratinfasern vor Insektenfrass und Mittel zur Durchführung dieses Verfahrens |
| US3655901A (en) | 1970-07-30 | 1972-04-11 | Merck & Co Inc | Method of inhibiting the formation of phenylethanalamine-n-methyl transferase with 2-aminobenzimidazoles |
| SE9003151D0 (sv) | 1990-10-02 | 1990-10-02 | Medivir Ab | Nucleoside derivatives |
| US5248672A (en) | 1990-11-01 | 1993-09-28 | The Regents Of The University Of Michigan | Polysubstituted benzimidazole nucleosides as antiviral agents |
| AU5447094A (en) | 1992-10-21 | 1994-05-09 | Regents Of The University Of Michigan, The | Polysubstituted benzimidazoles as antiviral agents |
| GB9413724D0 (en) * | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
| GB9600143D0 (en) | 1996-01-05 | 1996-03-06 | Wellcome Found | Therapeutic compounds |
| GB2319961A (en) | 1996-12-07 | 1998-06-10 | Glaxo Group Ltd | Pharmaceutical composition for treatment of restenosis |
| GB9807354D0 (en) | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
-
1998
- 1998-04-07 GB GBGB9807355.4A patent/GB9807355D0/en not_active Ceased
-
1999
- 1999-03-31 AR ARP990101493A patent/AR014973A1/es not_active Application Discontinuation
- 1999-03-31 CO CO99019384A patent/CO5011057A1/es unknown
- 1999-04-01 DK DK99919169T patent/DK1070078T3/da active
- 1999-04-01 HU HU0101549A patent/HUP0101549A3/hu unknown
- 1999-04-01 EP EP99919169A patent/EP1070078B1/en not_active Expired - Lifetime
- 1999-04-01 OA OA1200000263A patent/OA11534A/en unknown
- 1999-04-01 PT PT99919169T patent/PT1070078E/pt unknown
- 1999-04-01 AP APAP/P/2000/001946A patent/AP2000001946A0/en unknown
- 1999-04-01 IL IL13855999A patent/IL138559A0/xx active IP Right Grant
- 1999-04-01 SI SI9930241T patent/SI1070078T1/xx unknown
- 1999-04-01 DE DE69905025T patent/DE69905025T2/de not_active Expired - Lifetime
- 1999-04-01 YU YU58600A patent/YU58600A/sh unknown
- 1999-04-01 SK SK1482-2000A patent/SK283735B6/sk unknown
- 1999-04-01 BR BR9909471-1A patent/BR9909471A/pt not_active IP Right Cessation
- 1999-04-01 CA CA002327495A patent/CA2327495C/en not_active Expired - Lifetime
- 1999-04-01 AT AT99919169T patent/ATE231517T1/de active
- 1999-04-01 CN CNB998070084A patent/CN1222534C/zh not_active Expired - Lifetime
- 1999-04-01 TR TR2000/02847T patent/TR200002847T2/xx unknown
- 1999-04-01 ID IDW20002037A patent/ID26573A/id unknown
- 1999-04-01 BR BRPI9909471A patent/BRPI9909471B8/pt unknown
- 1999-04-01 ES ES99919169T patent/ES2191429T3/es not_active Expired - Lifetime
- 1999-04-01 PL PL343712A patent/PL194752B1/pl unknown
- 1999-04-01 NZ NZ507012A patent/NZ507012A/xx not_active IP Right Cessation
- 1999-04-01 JP JP2000542338A patent/JP2002510702A/ja active Pending
- 1999-04-01 GE GEAP19995570A patent/GEP20022840B/en unknown
- 1999-04-01 AU AU37038/99A patent/AU753527B2/en not_active Expired
- 1999-04-01 US US09/647,868 patent/US6482939B1/en not_active Expired - Lifetime
- 1999-04-01 EE EEP200000585A patent/EE04121B1/xx not_active IP Right Cessation
- 1999-04-01 EA EA200000909A patent/EA002953B1/ru not_active IP Right Cessation
- 1999-04-01 KR KR1020007011093A patent/KR100573635B1/ko not_active IP Right Cessation
- 1999-04-01 WO PCT/EP1999/002213 patent/WO1999051617A2/en active IP Right Grant
- 1999-04-05 EG EG35899A patent/EG24597A/xx active
- 1999-04-05 MA MA25520A patent/MA26617A1/fr unknown
- 1999-04-05 PE PE1999000264A patent/PE20000356A1/es not_active Application Discontinuation
-
2000
- 2000-09-19 IL IL138559A patent/IL138559A/en not_active IP Right Cessation
- 2000-09-22 IS IS5634A patent/IS5634A/is unknown
- 2000-09-27 ZA ZA200005197A patent/ZA200005197B/xx unknown
- 2000-10-04 NO NO20005003A patent/NO316896B1/no not_active IP Right Cessation
- 2000-10-09 HR HR20000670A patent/HRP20000670B1/xx not_active IP Right Cessation
- 2000-11-03 BG BG104909A patent/BG104909A/bg unknown
-
2001
- 2001-04-04 HK HK01102423A patent/HK1032060A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR014973A1 (es) | Forma vi de 5,6-dicloro-2-(isopropilamino)-1-beta-l-ribofuranosil-1h-bencimidazol, uso del mismo en la preparacion de medicamentos, formulaciones que lacontienen y procesos para su sintesis | |
| BR9812223A (pt) | Composto de metal misto, usos de um composto de metal misto e de um material de sulfato de metal, material de sulfato de metal, e, processo para preparar um material de sulfato de metal | |
| DK1914237T3 (da) | Antivirale fosfonatesterforbindelser | |
| ES2060002T3 (es) | Compuestos formadores de quelatos para la complejacion de isotopos radiactivos, sus complejos con metales, asi como su utilizacion en diagnostico y terapia. | |
| HK35597A (en) | New phospholipid derivatives of nucleosides their preparation and their use as antiviral drugs | |
| NL300224I2 (nl) | 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl- of indanylalkylaminoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen. | |
| ITFI910071U1 (it) | Piastra per osso per la porzione distale dell'omero. | |
| IE901862L (en) | Inclusion compound of imipramine | |
| DE50011687D1 (de) | Subgingivales pulverstrahlen | |
| AR061005A2 (es) | Forma cristalina a de 1-(2,6- difluorobencil)-1h-1,2,3- triazol-4-carboxamida, preparaciones farmaceuticas que las contienen y su uso para la preparacion de medicamentos | |
| DE69822668D1 (de) | Heterozyklische ether- und thioether-verbindungen, verwendbar zur steuerung von chemischer synaptischer transmission | |
| HUP0302327A2 (hu) | Ekteinaszcidin-származékok, alkalmazásuk, az ezeket tartalmazó gyógyszerkészítmények | |
| ATE155039T1 (de) | Mit zucker überzogene pharmazeutische dosierungseinheit | |
| EP1018548A4 (en) | COMPOSITION BASED ON GLYCOSYLCERAMIDE ALPHA CAPABLE OF POTENTIALIZING CELLULAR IMMUNOGENICITY | |
| ES2053906T3 (es) | Procedimiento para la obtencion de derivados de la 3,5-dimetil-4-metoxipiridina. | |
| ES503884A0 (es) | Procedimiento para la preparacion de nitratos de amino-deso-xi-1.4;3.6-dianhidro-hexito,asi como de sus sales de adicionacida farmacologicamente inocuas | |
| DE3066237D1 (en) | 6-substituted-arylpyrido(2,3-d)pyrimidin-7-amines, derivatives and salts thereof, pharmaceutical compositions containing any of the foregoing, and processes for producing any of the foregoing | |
| DE68902591D1 (de) | Roentgenstrahl-absorptionsmittel fuer roentgenstrahllithographie und herstellung durch zerstaeubung. | |
| ATE99945T1 (de) | Verwendung von 5'-deoxy-5'-methylthioadenosin s- adenosylmethionin und dessen salzen zur herstellung von seborrhea vermindernden arzneimitteln. | |
| MX173822B (es) | Procedimiento para el analisis de particulas metalicas | |
| ES2102430T3 (es) | Disulfuros, procedimiento para su obtencion y su empleo. | |
| DE69402576T2 (de) | Cytotoxische und antivirale Verbindung | |
| ES2192878T3 (es) | 4,5-azolo-oxindoles. | |
| ES2087279T3 (es) | El uso de giberelinas para el tratamiento de la prostatitis y la psoriasis. | |
| Font et al. | Finding the words: Instruments for a therapy of liberation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |